Battleground shopping: Big Pharma versus Indian Patent policy
On March 13th 2013, in a hearing before the US House of Representatives, Pfizer’s Chief Intellectual Property Counsel Roy Waldron derided India’s pharmaceutical patent regime stating amongst other things that India has ‘routinely flouted trade rules’, discriminating in favour of domestic generic companies, and is abusing the compulsory license system. Waldron went on to recommend that the US government use ‘every available bilateral and multilateral fora’ and ‘review all available policy tools’ in order to send strong signals to the […]
Battleground shopping: Big Pharma versus Indian Patent policy Read More »






